Such patients still require transfusion therapy (e

Such patients still require transfusion therapy (e.g., OHA patients). of units transfused, whether red blood cells (RBC) were washed and, finally, a section relating to the presence or absence of alloantibodies and their Rasagiline identification. == Results == Data was retrieved for 2,574 patients: 68.6% TM, 15.4% TI, 10.3% TD, 4.1% SCD, and 1.6% other hemoglobinopathies (OHA). The number of RBC units transfused was 76,974, equivalent to 24.5% of all the RBCU transfused from the total number of patients followed. The number of washed RBCU was 21.1% of all the units used; 337 patients (37%) were diagnosed with alloantibodies, the majority of which were patients with SCD (20.6%). Of the 485 alloantibodies found, 90.3% were identified. The antibodies found most frequently were related to the Kell system (41.7%) followed by antibodies to the Rhesus system (37.9%); 29.7% of patients had more than one antibody. == Discussion == From our study, certain indications can be formulated: complete the National Registry for patients with hemoglobinopathies; create a Registry of alloimmunized patients to ensure transfusion therapy is as safe as possible, considering antibody evanescence; and 3) increase the recruitment of blood donors of diverse ethnicities. Keywords:hemoglobinopathy, thalassemia, sickle cell disease, alloimmunization, transfusion == INTRODUCTION == Thalassemia is usually caused by genetic defects of the globin gene which lead to anemia, chronic transfusions and co-morbidity. Transfusion-dependent patients with thalassemia major (TM) or beta thalassemia intermedia (TI) suffer from a reduced life expectancy and from systemic pathology. This is in spite of recent improvements in clinical management that have reduced mortality and, more importantly, the current therapeutic use of gene therapy as a functional cure1. The most recent classification of thalassemia syndromes distinguishes autosomal recessive conditions, heterozygosity for alpha and beta thalassemia which are generally asymptomatic and do not require treatment. Homozygosity and combined heterozygosity with other thalassemia mutations determine the thalassemic syndromes. Hence the conversation between thalassemia and other hemoglobinopathies, Rasagiline for example, HbE, HbC, or HbS with beta thalassemia or with Hb Constant Spring (HbCS) with alpha thalassemia, will determine the presence of the various thalassemic syndromes. Currently, based on the clinical severity of these syndromes and on the necessity Rasagiline for chronic transfusion therapy, thalassemic syndromes can be classified into two main groups: transfusion-dependent thalassemia (TDT) or non-transfusion-dependent thalassemia (NTDT). TDT requires regular and constant transfusion therapy for survival; in the absence of this critical support, TDT patients will present with severe complications and a markedly reduced life expectancy. The TDT category includes patients with TM, while the NTDT category includes patients with TI2. The optimization of therapy, including iron chelation, leads to doubts as to whether there is a case for modifying this distinction, at least with regards to life expectancy3. Transfusion therapy remains an important support in the management of patients with SCD and TD. It is used both in acute and chronic events but may have collateral effects such as alloimmunization and iron overload4,5. == MATERIALS AND METHODS == The collected and processed data offer a picture of the presence of hemoglobinopathies in Sicily and Sardinia, and in the Maltese islands. Similarly, as highlighted by the Italian Society Rasagiline of Thalassaemia and Hemoglobinopathies (SITE), not all the centers treating patients with hemoglobinopathies are identified as a transfusion support (TS). Therefore, the generic term Rabbit Polyclonal to SIAH1 TS is used to facilitate the description of the type of data and the activities undertaken. Clearly the management of thalassemic patients is not limited to transfusions. Following this logic, the collected data provide an assessment of the typical activities of the TS: number of pre-storage filtered red blood cell (RBC) units utilized, with the aim of programming Rasagiline collection, or the inter-regional exchange of RBC units to ensure patient access transfusion therapy; number of washed units, the methodology adopted and the reason for the procedure; whether exchange transfusions (EEX) are carried out, by which method (manual or by cell separators), and whether these processes are carried out within the TS or at other operational units. The final part of the questionnaire concerns the type of pathology: which patient blood groups are defined in cases of inclusion for transfusion therapy; how many patients have developed irregular antibodies; whether these antibodies have been identified and their specificity. In April 2022, a questionnaire was sent to the TS of Sicily and Sardinia, and to the Maltese Country wide Blood Transfusion assistance (MNBT) for the removal of data in accordance with 2021. A complete of 38 questionnaires had been delivered: 31 towards the TS of the spot of Sicily, six towards the TS of Sardinia, and someone to the.